Group 1 - The stock of Hongyuan Pharmaceutical reached the daily limit, with a turnover rate of 27.00% and a transaction amount of 722 million yuan, showing a volatility of 24.58% [1] - Institutional investors net bought 11.43 million yuan, while the Shenzhen Stock Connect recorded a net purchase of 13.67 million yuan, with a total net buying from brokerage seats amounting to 55.99 million yuan [1] - The stock was listed on the Shenzhen Stock Exchange due to a closing price increase of 20.00%, with the top five trading seats collectively transacting 180 million yuan, including a buying amount of 131 million yuan and a selling amount of 49.42 million yuan, resulting in a net purchase of 81.10 million yuan [1] Group 2 - As of October 10, the latest margin trading balance for the stock was 95.78 million yuan, with a financing balance of 95.59 million yuan and a securities lending balance of 196,000 yuan [2] - Over the past five days, the financing balance decreased by 494,100 yuan, reflecting a decline of 0.51% [2]

Core Points - Hongyuan Pharmaceutical (301246.SZ) reported a revenue of 883 million yuan for the first half of 2025, a year-on-year decrease of 1.73% [1] - The net profit attributable to shareholders was -5.81 million yuan, compared to a profit of 35.81 million yuan in the same period last year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -21.59 million yuan, down from 14.68 million yuan year-on-year [1] - The net cash flow from operating activities was -170 million yuan, compared to -18.46 million yuan in the previous year [1] Fundraising and IPO Details - Hongyuan Pharmaceutical raised a total of 2.36 billion yuan from its initial public offering, with a net amount of 2.20 billion yuan after deducting issuance costs [2] - The final net fundraising amount exceeded the original plan by 1.55 billion yuan [2] - The company initially planned to raise 650 million yuan for projects including a research center and a high-end formulation workshop with an annual production capacity of 2.5 billion pieces [2] - The total issuance costs amounted to 167 million yuan, with underwriting fees accounting for 139.32 million yuan [2]

10月13日消息，截止13:50，六氟磷酸锂板块强势，石大胜华、天际股份、多氟多涨停，宏源药业、天 赐材料等个股涨幅居前。 责任编辑：小浪快报 ...

Core Insights - Hongyuan Pharmaceutical (301246) invests nearly 70 million yuan annually in R&D and collaborates deeply with universities such as Fudan University and Wuhan University, establishing a comprehensive innovation system [1] - The company holds 65 patents, including 57 invention patents, and has received multiple provincial science and technology progress awards for its innovative processes [1] - In the pharmaceutical sector, Hongyuan has built a complete industrial chain covering nitroimidazole antibacterial drugs, becoming a major global supplier with leading market share in core products [1] - In the new energy sector, the company has developed a "rheological reverse reaction method for preparing lithium hexafluorophosphate" in collaboration with Wuhan University, achieving international advanced levels and becoming a supplier for BYD (002594) [1] - Hongyuan is advancing its "third-generation" lithium hexafluorophosphate technology and is scaling up a 6000-ton high-purity crystal project, which is expected to enhance its market share in the electrolyte sector upon production [1]

Market Overview - The Shanghai Composite Index closed at 3872.88 points, up 1.17%, with a total trading volume of 1.7438 trillion yuan [1] - As of the current date, 94 A-shares have surpassed their annual moving average [1] Stocks Surpassing Annual Moving Average - Notable stocks with significant deviation rates include: - Kaiwang Technology (301182) with a deviation rate of 15.21% and a daily increase of 17.68% [1] - Wanli Stone (002785) with a deviation rate of 9.52% and a daily increase of 10.01% [1] - Daqing Huake (000985) with a deviation rate of 9.44% and a daily increase of 10.00% [1] - Other stocks with smaller deviation rates include: - China CNR (601990) and Beidahuang (000995), both just above their annual moving average [1] Additional Stocks with Positive Performance - Other stocks showing positive performance include: - Tonghui Information (430090) with a daily increase of 6.20% and a deviation rate of 4.69% [1] - Huangtai Liquor (000995) with a daily increase of 5.17% and a deviation rate of 4.47% [1] - Nanjing Securities (601990) with a daily increase of 4.09% and a deviation rate of 4.00% [1]

宏源药业（301246.SZ）9月23日在投资者互动平台表示，子公司宏源堂药业是2024年收购的，是一家医 药商业企业，今年已实现营业收入，并不断开拓市场份额，详细情况请关注公司的信息披露。 （记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：子公司宏源堂药业今年销量如何？推出了哪些爆款药 品？ ...

证券代码：301246 证券简称：宏源药业 公告编号：2025-040 湖北省宏源药业科技股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会召开期间没有增加或变更议案； 3、本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 （1）现场会议召开时间：2025 年 9 月 15 日（星期一）下午 14:30 （2）网络投票时间：2025 年 9 月 15 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 9 月 15 日上午 9:15–9:25，9:30-11:30，下午 13:00-15:00； 通过深圳证券交易所互联网投票的具体时间为：2025 年 9 月 15 日（星期一） 9:15-15:00 的任意时间。 2、现场会议出席情况 出席本次股东大会现场会议的股东及股东代表 14 名，代表公司有表决权的 股份 243,318,800 股，占公司有表决权股 ...

本所及本所律师依据法律法规及本法律意见出具日以前已经发生或者存在的事实, 严 格履行了法定职责, 遵循了勤勉尽责和诚实信用原则, 进行了充分的核查验证, 保证本法律 意见所认定的事实真实、准确、完整, 所发表的结论性意见合法、准确, 不存在虚假记载、 误导性陈述或者重大遗漏, 并承担相应法律责任。 在此基础上, 本所律师出具法律意见如下: 24SH7200110/PC/pz/cm/D5 上海市通力律师事务所 关于湖北省宏源药业科技股份有限公司 2025 年第二次临时股东大会的法律意见书 致: 湖北省宏源药业科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受湖北省宏源药业科技股份有限公司(以 下简称"公司")的委托, 指派本所纪宇轩律师、赵伯晓律师(以下简称"本所律师")根据 《中华人民共和国公司法》《中华人民共和国证券法》等法律法规和规范性文件(以下统称"法 律法规")及《湖北省宏源药业科技股份有限公司章程》(以下简称"公司章程")的规定就 公司 2025 年第二次临时股东大会(以下简称"本次股东大会")相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予 ...

证券代码：301246 证券简称：宏源药业 公告编号：2025-041 湖北省宏源药业科技股份有限公司 买卖公司股票情况的自查报告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 湖北省宏源药业科技股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开了第四届董事会第十一次会议、第四届监事会第十次会议，审议通过了《关 于<2025 年限制性股票激励计划（草案）>及其摘要的议案》等相关议案。具体 内容详见公司于 2025 年 8 月 28 日在中国证券监督管理委员会（以下简称"中国 证监会"）指定的创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露 了《2025 年限制性股票激励计划（草案）》及其摘要、《2025 年限制性股票激 励计划实施考核管理办法》等相关文件。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深 圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》（以下简称 "《自律监管指南第 1 号》"）等有关法律法规及规范性文件的相关规定，公司 通过向中国证券登记结算有限责任公司深圳 ...

证券日报网讯宏源药业（301246）9月12日在互动平台回答投资者提问时表示，目前公司已完成公斤级 硫化物电解质前驱体及电解质样品制备，并进行测试优化工作。公司的产品生产情况及规划请关注公司 的信息披露。 ...